Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides.

Date publication

octobre 2013

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard

Tous les auteurs :
Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla E, Hamidou M, Harle JR, Karras A, Lega JC, Le Quellec A, Mahr AD, Mouthon L, Papo T, Puechal X, Pugnet G, Samson M, Sibilia J, Terrier B, Vandergheynst F, Guillevin L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24095054

Résumé

Increasing rituximab prescription for ANCA-associated necrotizing vasculitides justifies the publication of recommendations for clinicians. Rituximab is approved in the United States to induce and maintain remission. In Europe, rituximab was recently approved for remission induction. However, governmental agencies' approvals cannot replace clinical practice guidelines. Herein, the French Vasculitis Study Group Recommendations Committee, comprised of physicians with extensive experience in the treatment of vasculitides, presents its consensus guidelines based on literature analysis, the results of prospective therapeutic trials and personal experience.

Référence

Presse Med. 2013 Oct;42(10):1317-30